Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
About Agios Pharmaceuticals, Inc.
- NASDAQ: $AGIO
- Notified: $48.83
- 07:00 EDT
